Want to see HK:1244 full AI Analyst Report?
3D Medicines, Inc. (1244) AI Stock Analysis
3D Medicines, Inc.
(HKEX:1244)
The score is primarily weighed down by weak financial performance (ongoing losses and negative free cash flow despite improving loss trends). Technicals are a notable offset, with the stock trading above major moving averages and positive momentum signals. Valuation is constrained by negative earnings and no indicated dividend yield.
3D Medicines, Inc. (1244) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 641.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 168.88K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.61
- Revenue Growth
- -17.22%
- EPS Growth
- -6.13%
- Country
- Hong Kong
- Employees
- 162
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
3D Medicines, Inc. Business Overview & Revenue Model
Company Description
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to...
3D Medicines, Inc. Financial Statement Overview
Summary
Income statement and cash flow are weak: revenue has contracted and the company remains loss-making with negative operating and free cash flow (cash burn persists). Positives include very high gross margin and meaningfully narrowing losses versus prior years. Balance sheet leverage appears moderate, but equity has been trending down alongside ongoing losses.
Income Statement
28NegativeBalance Sheet
54NeutralCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 357.68M | 356.09M | 445.65M | 634.95M | 567.39M | 60.26M |
| Gross Profit | 316.66M | 298.97M | 371.74M | 524.01M | 525.18M | 55.98M |
| EBITDA | -166.51M | -191.18M | -209.56M | -529.23M | -1.03B | -1.45B |
| Net Income | -173.50M | -177.53M | -182.66M | -524.70M | -1.02B | -1.43B |
Balance Sheet | ||||||
| Total Assets | 937.55M | 936.64M | 1.22B | 1.43B | 1.33B | 1.06B |
| Cash, Cash Equivalents and Short-Term Investments | 394.59M | 438.10M | 840.98M | 996.58M | 942.03M | 824.48M |
| Total Debt | 171.36M | 152.85M | 237.62M | 282.43M | 175.70M | 3.15B |
| Total Liabilities | 467.15M | 391.54M | 512.54M | 558.20M | 436.65M | 3.33B |
| Stockholders Equity | 524.89M | 596.98M | 785.06M | 936.74M | 943.00M | -2.24B |
Cash Flow | ||||||
| Free Cash Flow | -174.91M | -149.87M | -249.60M | -150.74M | -332.76M | -433.46M |
| Operating Cash Flow | -174.36M | -149.85M | -210.58M | -144.41M | -278.78M | -377.08M |
| Investing Cash Flow | 97.88M | -26.20M | 17.95M | -187.58M | -242.11M | -98.87M |
| Financing Cash Flow | -9.36M | -89.56M | -33.92M | 304.51M | 408.41M | 840.08M |
3D Medicines, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Positive. The current price of 2.69 is above the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.61, and below the 200-day MA of 3.26, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1244.
3D Medicines, Inc. Peers Comparison
Overall Rating
HK:996652Neutral- HK:124452Neutral
HK:212649Neutral
HK:217145Neutral
HK:225742Neutral
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9966 | 52Neutral | HKD 6.06B | -30.61 | -10.27% | ― | -31.77% | -177.01% |
| HK:1244 | 52Neutral | HKD 673.84M | -3.11 | -30.93% | ― | -17.22% | -6.13% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2126 | 49Neutral | HKD 925.48M | -2.35 | -66.16% | ― | 67.48% | 43.84% |
| HK:2171 | 45Neutral | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
| HK:2257 | 42Neutral | HKD 463.21M | -4.83 | 133.13% | ― | -100.00% | 30.94% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1244 | 3D Medicines, Inc. | 2.61 | -3.53 | -57.49% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:2126 | JW (Cayman) Therapeutics Co. Ltd. | 2.22 | -1.82 | -45.05% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2257 | Sirnaomics Ltd. | 4.13 | -5.64 | -57.73% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% |
3D Medicines, Inc. Corporate Events
3D Medicines Hits Key Phase 3 Milestone for AML Vaccine Candidate
3D Medicines Inc. announced significant progress in its collaboration with SELLAS Life Sciences on 3D189 (Galinpepimut-S, GPS), an investigational WT1 tumor vaccine for acute myeloid leukemia and the company’s second product nearing commerciali...
3D Medicines Updates Cayman Share Registrar, Keeps Hong Kong Arrangements Intact
3D Medicines Inc. has changed the address of its principal share registrar and transfer office in the Cayman Islands, effective September 30, 2026, appointing Ascentium (Cayman) Limited at a new Grand Cayman location to handle its primary share regis...
3D Medicines Extends HK$50 Million Note at Higher Coupon
3D Medicines (Hong Kong) Co., Limited, a wholly owned subsidiary of 3D Medicines Inc., has extended a short-term note investment with independent third party Mega Link International Limited, maintaining a principal of HK$50 million. The extension ref...
3D Medicines Boosts Envafolimab Sales and Deepens Oncology Pipeline in H1 2026
3D Medicines reported interim unaudited results for the six months to June 30, 2026, highlighting steady commercial progress and pipeline advancement. Envafolimab generated RMB210.5 million in sales in China, up 0.6% year-on-year and 43% sequentially...
3D Medicines Fully Enforces Arbitration Win Against SELLAS as Key Trial Nears Endpoint
3D Medicines Inc. has secured full payment of HK$7,983,004.42 from SELLAS Life Sciences Group Inc., following an arbitral tribunal’s dismissal of all claims brought by SELLAS in a licence‑related dispute and its order that SELLAS bear the...
3D Medicines Sets Board Meeting to Approve Interim Results and Consider Dividend
3D Medicines Inc., a Cayman Islands–incorporated biopharmaceutical firm listed in Hong Kong, develops and commercializes innovative healthcare products through its subsidiaries. The group’s governance is overseen by a diversified board th...
3D Medicines Revamps Board as Finance Veteran Joins After Non-Executive Director Steps Down
3D Medicines Inc. has announced a board reshuffle, with non-executive director Mr. Zhu Jinqiao set to retire on August 7, 2026, to focus on other professional commitments. The company emphasized that Mr. Zhu leaves without disagreement with the board...
3D Medicines Details Board and Committee Structure
3D Medicines Inc. announced the current composition of its board of directors, listing one executive director, three non-executive directors and three independent non-executive directors. The company also detailed the structure of its audit, remunera...
3D Medicines Updates Hong Kong Process Agent and Moves Principal Office
3D Medicines Inc. has appointed Ms. Leung Ching Ching as its new agent for the acceptance of service of process and notices in Hong Kong, replacing Ms. Li Ching Yi with effect from August 4, 2026. This change in process agent strengthens the company&...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026